Cargando…

A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival

INTRODUCTION: The incidence and mortality rates of cutaneous melanoma (CM) are increasing among fair-skinned populations worldwide. Ultraviolet radiation (UVR) is the principal risk factor for CM, but is also the main source of 25-hydroxyvitamin D (25(OH)D), which has been associated with reduced ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Stenehjem, Jo Steinson, Grimsrud, Tom K, Rees, Judith R, Vos, Linda, Babigumira, Ronnie, Veierød, Marit B, Robsahm, Trude Eid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623373/
https://www.ncbi.nlm.nih.gov/pubmed/28637727
http://dx.doi.org/10.1136/bmjopen-2016-014829
_version_ 1783268071056605184
author Stenehjem, Jo Steinson
Grimsrud, Tom K
Rees, Judith R
Vos, Linda
Babigumira, Ronnie
Veierød, Marit B
Robsahm, Trude Eid
author_facet Stenehjem, Jo Steinson
Grimsrud, Tom K
Rees, Judith R
Vos, Linda
Babigumira, Ronnie
Veierød, Marit B
Robsahm, Trude Eid
author_sort Stenehjem, Jo Steinson
collection PubMed
description INTRODUCTION: The incidence and mortality rates of cutaneous melanoma (CM) are increasing among fair-skinned populations worldwide. Ultraviolet radiation (UVR) is the principal risk factor for CM, but is also the main source of 25-hydroxyvitamin D (25(OH)D), which has been associated with reduced risk and better prognosis of some cancer types. However, both low and high 25(OH)D levels have been associated with increased risk of CM. Obesity as measured by body mass index (BMI) is associated with risk of several cancers and has also been suggested as a risk factor for CM, and may also be related to insufficient 25(OH)D and/or high leptin levels. Moreover, contracting a CM diagnosis has been associated with increased risk of developing second cancer. We aim to study whether low prediagnostic serum levels of 25(OH)D, high prediagnostic levels of BMI and high serum leptin levels influence CM incidence, Breslow thickness and CM mortality, and risk of second cancer and survival after a CM diagnosis. METHODS AND ANALYSIS: Cohort and nested case–control studies will be carried out using the population-based Janus Serum Bank Cohort (archival prediagnostic sera, BMI, smoking and physical activity), with follow-up from 1972 to 2014. Additional data will be received from the Cancer Registry of Norway, the national Cause of Death Registry, Statistics Norway (education and occupation) and exposure matrices of UVR. Time-to-event regression models will be used to analyse the cohort data, while the nested case–control studies will be analysed by conditional logistic regression. A multilevel approach will be applied when incorporating group-level data. ETHICS AND DISSEMINATION: The project is approved by the Regional Committee for Medical Research Ethics and is funded by the Norwegian Cancer Society. Results will be published in peer-reviewed journals, at scientific conferences and in the news media.
format Online
Article
Text
id pubmed-5623373
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56233732017-10-10 A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival Stenehjem, Jo Steinson Grimsrud, Tom K Rees, Judith R Vos, Linda Babigumira, Ronnie Veierød, Marit B Robsahm, Trude Eid BMJ Open Epidemiology INTRODUCTION: The incidence and mortality rates of cutaneous melanoma (CM) are increasing among fair-skinned populations worldwide. Ultraviolet radiation (UVR) is the principal risk factor for CM, but is also the main source of 25-hydroxyvitamin D (25(OH)D), which has been associated with reduced risk and better prognosis of some cancer types. However, both low and high 25(OH)D levels have been associated with increased risk of CM. Obesity as measured by body mass index (BMI) is associated with risk of several cancers and has also been suggested as a risk factor for CM, and may also be related to insufficient 25(OH)D and/or high leptin levels. Moreover, contracting a CM diagnosis has been associated with increased risk of developing second cancer. We aim to study whether low prediagnostic serum levels of 25(OH)D, high prediagnostic levels of BMI and high serum leptin levels influence CM incidence, Breslow thickness and CM mortality, and risk of second cancer and survival after a CM diagnosis. METHODS AND ANALYSIS: Cohort and nested case–control studies will be carried out using the population-based Janus Serum Bank Cohort (archival prediagnostic sera, BMI, smoking and physical activity), with follow-up from 1972 to 2014. Additional data will be received from the Cancer Registry of Norway, the national Cause of Death Registry, Statistics Norway (education and occupation) and exposure matrices of UVR. Time-to-event regression models will be used to analyse the cohort data, while the nested case–control studies will be analysed by conditional logistic regression. A multilevel approach will be applied when incorporating group-level data. ETHICS AND DISSEMINATION: The project is approved by the Regional Committee for Medical Research Ethics and is funded by the Norwegian Cancer Society. Results will be published in peer-reviewed journals, at scientific conferences and in the news media. BMJ Publishing Group 2017-06-21 /pmc/articles/PMC5623373/ /pubmed/28637727 http://dx.doi.org/10.1136/bmjopen-2016-014829 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Epidemiology
Stenehjem, Jo Steinson
Grimsrud, Tom K
Rees, Judith R
Vos, Linda
Babigumira, Ronnie
Veierød, Marit B
Robsahm, Trude Eid
A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival
title A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival
title_full A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival
title_fullStr A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival
title_full_unstemmed A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival
title_short A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival
title_sort protocol for prospective studies of 25-hydroxyvitamin d, leptin and body mass index in relation to cutaneous melanoma incidence and survival
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623373/
https://www.ncbi.nlm.nih.gov/pubmed/28637727
http://dx.doi.org/10.1136/bmjopen-2016-014829
work_keys_str_mv AT stenehjemjosteinson aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT grimsrudtomk aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT reesjudithr aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT voslinda aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT babigumiraronnie aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT veierødmaritb aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT robsahmtrudeeid aprotocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT stenehjemjosteinson protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT grimsrudtomk protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT reesjudithr protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT voslinda protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT babigumiraronnie protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT veierødmaritb protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival
AT robsahmtrudeeid protocolforprospectivestudiesof25hydroxyvitamindleptinandbodymassindexinrelationtocutaneousmelanomaincidenceandsurvival